H3 receptor antagonist

A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease

Authors: Richard A Grove, Conn M Harrington, Andreas Mahler, Isabel Beresford, Paul Maruff, Martin T Lowy, Andrew P Nicholls, Rebecca L Boardley, Alienor C Berges, Pradeep J Nathan, Joseph P Horrigan

Journal: Current Alzheimer Research

Year Published: 2014

Introduction: Histaminergic H3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H3 receptor antagonist as monotherapy treatment […]

Back to Publications